← Back to All US Stocks

Opko Health, Inc.. (OPK) Stock Fundamental Analysis & AI Rating 2026

OPK Nasdaq Pharmaceutical Preparations DE CIK: 0000944809
Recently Updated • Analysis: Apr 13, 2026 • SEC Data: 2025-12-31
STRONG SELL
85% Conf
Pending
Analysis scheduled

📊 OPK Key Takeaways

Revenue: $606.9M
Net Margin: -37.2%
Free Cash Flow: $-190.8M
Current Ratio: 3.97x
Debt/Equity: 0.27x
EPS: $-0.30
AI Rating: STRONG SELL with 85% confidence
Opko Health, Inc.. (OPK) receives a STRONG SELL rating with 85% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $606.9M, net profit margin of -37.2%, and return on equity (ROE) of -17.8%, Opko Health, Inc.. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete OPK stock analysis for 2026.

Is Opko Health, Inc.. (OPK) a Good Investment?

Claude

OPKO Health is in severe operational distress with revenue declining 14.9% YoY, massive operating losses of -$117.4M (-19.3% margin), and catastrophic net losses of -$225.7M (-37.2% margin). Most critically, the company is burning cash operationally at -$178.5M with negative free cash flow of -$190.8M, indicating fundamental business model failure. While the balance sheet provides temporary runway, current operational performance is unsustainable and threatens shareholder value.

Why Buy Opko Health, Inc.. Stock? OPK Key Strengths

Claude
  • + Excellent liquidity position with 3.97x current ratio and 3.52x quick ratio
  • + Strong balance sheet with $364.4M in cash and low leverage (0.27x debt/equity ratio)
  • + Adequate gross margin of 33.9% suggests some core product viability despite volume declines

OPK Stock Risks: Opko Health, Inc.. Investment Risks

Claude
  • ! Revenue declining 14.9% YoY with no apparent turnaround in sight
  • ! Negative operating cash flow of -$178.5M indicates core business is not generating cash
  • ! Massive net losses of -$225.7M deteriorating 324% YoY signals deepening fundamental problems
  • ! Current burn rate unsustainable; cash reserves will be depleted without operational improvement
  • ! Negative operating margin of -19.3% indicates severe cost structure problems relative to revenue

Key Metrics to Watch

Claude
  • * Quarterly revenue trends and growth trajectory reversal
  • * Operating cash flow stabilization and path to positive territory
  • * Operating margin improvement and cost structure reduction initiatives
  • * Cash burn rate and runway extension with current balance sheet
  • * Product pipeline approvals and new revenue stream launches

Opko Health, Inc.. (OPK) Financial Metrics & Key Ratios

Revenue
$606.9M
Net Income
$-225.7M
EPS (Diluted)
$-0.30
Free Cash Flow
$-190.8M
Total Assets
$1.9B
Cash Position
$364.4M

💡 AI Analyst Insight

Strong liquidity with a 3.97x current ratio provides a solid financial cushion.

OPK Profit Margin, ROE & Profitability Analysis

Gross Margin 33.9%
Operating Margin -19.3%
Net Margin -37.2%
ROE -17.8%
ROA -11.7%
FCF Margin -31.4%

OPK vs Healthcare Sector: How Opko Health, Inc.. Compares

How Opko Health, Inc.. compares to Healthcare sector averages

Net Margin
OPK -37.2%
vs
Sector Avg 12.0%
OPK Sector
ROE
OPK -17.8%
vs
Sector Avg 15.0%
OPK Sector
Current Ratio
OPK 4.0x
vs
Sector Avg 2.0x
OPK Sector
Debt/Equity
OPK 0.3x
vs
Sector Avg 0.6x
OPK Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Opko Health, Inc.. Stock Overvalued? OPK Valuation Analysis 2026

Based on fundamental analysis, Opko Health, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-17.8%
Sector avg: 15%
Net Profit Margin
-37.2%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.27x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Opko Health, Inc.. Balance Sheet: OPK Debt, Cash & Liquidity

Current Ratio
3.97x
Quick Ratio
3.52x
Debt/Equity
0.27x
Debt/Assets
34.4%
Interest Coverage
N/A
Long-term Debt
$344.0M

OPK Revenue & Earnings Growth: 5-Year Financial Trend

OPK 5-year financial data: Year 2021: Revenue $1.8B, Net Income -$314.9M, EPS $-0.53. Year 2022: Revenue $1.8B, Net Income $30.6M, EPS $0.05. Year 2023: Revenue $1.8B, Net Income -$30.1M, EPS N/A. Year 2024: Revenue $1.0B, Net Income -$328.4M, EPS $-0.12. Year 2025: Revenue $863.5M, Net Income -$188.9M, EPS $-0.25.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Opko Health, Inc..'s revenue has declined by 51% over the 5-year period, indicating business contraction. The most recent EPS of $-0.25 indicates the company is currently unprofitable.

OPK Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-31.4%
Free cash flow / Revenue

OPK Quarterly Earnings & Performance

Quarterly financial performance data for Opko Health, Inc.. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $151.7M $21.6M $0.03
Q2 2025 $156.8M -$10.3M $-0.01
Q1 2025 $150.0M -$67.6M N/A
Q3 2024 $173.6M $24.9M $0.03
Q2 2024 $182.2M -$10.3M N/A
Q1 2024 $173.7M -$18.3M N/A
Q3 2023 $178.6M -$84.5M N/A
Q2 2023 $265.4M -$19.6M N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Opko Health, Inc.. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$178.5M
Cash generated from operations
Stock Buybacks
$47.0M
Shares repurchased (TTM)
Capital Expenditures
$12.3M
Investment in assets
Dividends Paid
$4.7M
Returned to shareholders

OPK SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Opko Health, Inc.. (CIK: 0000944809)

📋 Recent SEC Filings

Date Form Document Action
Mar 20, 2026 4 xslF345X06/ownership.xml View →
Mar 20, 2026 4 xslF345X06/ownership.xml View →
Mar 19, 2026 8-K opk-20260318.htm View →
Feb 26, 2026 10-K opk-20251231.htm View →
Feb 26, 2026 8-K opk-20260226.htm View →

Frequently Asked Questions about OPK

What is the AI rating for OPK?

Opko Health, Inc.. (OPK) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.

What are OPK's key strengths?

Claude: Excellent liquidity position with 3.97x current ratio and 3.52x quick ratio. Strong balance sheet with $364.4M in cash and low leverage (0.27x debt/equity ratio).

What are the risks of investing in OPK?

Claude: Revenue declining 14.9% YoY with no apparent turnaround in sight. Negative operating cash flow of -$178.5M indicates core business is not generating cash.

What is OPK's revenue and growth?

Opko Health, Inc.. reported revenue of $606.9M.

Does OPK pay dividends?

Opko Health, Inc.. pays dividends, with $4.7M distributed to shareholders in the trailing twelve months.

Where can I find OPK SEC filings?

Official SEC filings for Opko Health, Inc.. (CIK: 0000944809) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is OPK's EPS?

Opko Health, Inc.. has a diluted EPS of $-0.30.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is OPK a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Opko Health, Inc.. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is OPK stock overvalued or undervalued?

Valuation metrics for OPK: ROE of -17.8% (sector avg: 15%), net margin of -37.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy OPK stock in 2026?

Our dual AI analysis gives Opko Health, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is OPK's free cash flow?

Opko Health, Inc..'s operating cash flow is $-178.5M, with capital expenditures of $12.3M. FCF margin is -31.4%.

How does OPK compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -37.2% (avg: 12%), ROE -17.8% (avg: 15%), current ratio 3.97 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 13, 2026 | Data as of: 2025-12-31 | Powered by Claude AI